CoChat

Is There a Link Between Liraglutide and Pancreatitis? A Post Hoc Review of Pooled and Patient-Level Data From Completed Liraglutide Type 2 Diabetes Clinical Trials

The DOI matches its Crossref record; 34 of the 36 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To report the incidence of pancreatitis in type 2 diabetes trials of liraglutide and details of all pancreatitis cases. RESEARCH DESIGN AND METHODS: Data from Novo Nordisk–sponsored trials with liraglutide (phase 2 and 3; NN2211 identifiers) completed by 19 April 2013 were pooled. All pancreatitis cases were reviewed. RESULTS: Total exposure to liraglutide and active comparators was 5,021 and 1,354 patient-years, respectively (n = 6,345 and 1,846, respectively). Eight cases of acute pancreatitis (AP) with liraglutide and one with any comparator (glimepiride) were found. The incidence of AP was 1.6 cases/1,000 patient-years exposure (PYE) for liraglutide vs. 0.7 cases/1,000 PYE for total active comparators. One of the eight AP cases reported with liraglutide did not meet diagnostic criteria for AP. In six of these eight cases, recognized risk factors for AP were present and/or the onset of AP occurred >6 months after liraglutide initiation. All patients were receiving multiple medications. Four cases of chronic pancreatitis (CP) with liraglutide and none with comparators were found. One of these four cases fulfilled diagnostic criteria for CP; these criteria were not met or information was missing in the remaining three. CONCLUSIONS: Based on the small number of cases observed, the incidences of reported AP and CP were numerically greater with liraglutide than with comparators. Not all cases fulfilled diagnostic criteria, and confounding variables were present in 75% of the AP cases with liraglutide therapy, precluding firm conclusions.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc13-1210

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 34 references

Research works printed but not linked: 1

  1. Gourdy, 2013, Effectiveness and persistence with liraglutide among patients with type 2 diabetes. One year data from EVIDENCE: a 2-year, prospective, follow up, post-marketing study (Abstract), Diabetologia, 56, S369

Cited by

See all 50

Metadata

Authors
Jensen, T. M., Saha, K., & Steinberg, W. M.
Affiliations
  • UK Medical Affairs, Novo Nordisk Ltd., Gatwick, U.K.
  • Novo Nordisk (Denmark) (DK)
  • George Washington University (US)
Corresponding author
Jensen, Troels M.
Venue
Diabetes Care
Published
2015-05-12
Volume
38
Issue
6
Pages
1058-1066
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2098737080
Cited by
48
References
36
Citations by year
2026: 1 · 2024: 3 · 2023: 3 · 2022: 3 · 2020: 4 · 2019: 6 · 2018: 4 · 2017: 6 · 2016: 8 · 2015: 10
FWCI
1.27
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
liraglutide, pancreatitis, acute pancreatitis, chronic pancreatitis, type 2 diabetes, GLP-1 receptor agonists, drug safety, glimepiride, risk factors, confounding
MeSH terms
Liraglutide, Acute Disease, Adult, Aged, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Pancreatitis, Risk Factors, Sulfonylurea Compounds, Randomized Controlled Trials as Topic, Pancreatitis, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Is There a Link Between Liraglutide and Pancreatitis? A Post Hoc Review of Pooled and Patient-Level Data From Completed Liraglutide Type 2 Diabetes Clinical Trials. https://app.cochat.ai/papers/10.2337/dc13-1210
The paper
Jensen, T. M., Saha, K., & Steinberg, W. M. (2015). Is There a Link Between Liraglutide and Pancreatitis? A Post Hoc Review of Pooled and Patient-Level Data From Completed Liraglutide Type 2 Diabetes Clinical Trials. Diabetes Care. https://doi.org/10.2337/dc13-1210

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.